Nicotine receptor partial agonists for smoking cessation

Cahill, Kate; Lindson, Nicola; Thomas, Kyla H; Fanshawe, Thomas R; Lancaster, Tim

doi:10.1002/14651858.cd006103.pub7

Cited by 291 publications

(226 citation statements)

References 213 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…Similarly, buproprion, an anti-depressant, and nicotine replacement therapy via a patch or gum have been shown to be more efficacious in promoting abstinence compared to placebo treatment [60]. A Cochrane systematic review suggested that personalized weight support and counseling may successfully reduce post-cessation weight gain.…”

Section: Smoking Cessation and Glucose Homeostasismentioning

confidence: 99%

Smoking and the risk of type 2 diabetes

Maddatu

Anderson-Baucum

Evans‐Molina

2017

Translational Research

275

168

View full text Add to dashboard Cite

Despite accumulating evidence demonstrating strong epidemiological and mechanistic associations between cigarette smoking, hyperglycemia, and the development of type 2 diabetes, tobacco abuse has not been uniformly recognized as a modifiable risk factor in diabetes prevention or screening strategies. In this review, we highlight population-based studies that have linked cigarette smoking with an increased risk of type 2 diabetes and summarize clinical and preclinical studies offering insight into mechanisms through which cigarette smoking and nicotine exposure impact body composition, insulin sensitivity, and pancreatic β cell function. Key questions for future studies are identified and strategies for smoking cessation as a means to decrease diabetes risk are discussed.

show abstract

Section: Smoking Cessation and Glucose Homeostasismentioning

confidence: 99%

Smoking and the risk of type 2 diabetes

Maddatu

Anderson-Baucum

Evans‐Molina

2017

Translational Research

275

168

View full text Add to dashboard Cite

show abstract

“…The latter serves as a partial agonist at these receptors, acting as a weak agonist in the absence of nicotine, and as a partial antagonist in the presence of nicotine 17 . While the in vitro receptor binding mechanisms of these drugs and their efficacy at a clinical level is established [18][19][20] , it is less clear how their systemslevel neurobiological mechanisms affect the cognitive and affective deficits seen in the human NWS.…”

Section: Introductionmentioning

confidence: 99%

Nicotine dependence (trait) and acute nicotinic stimulation (state) modulate attention but not cognitive control: converging fMRI evidence from Go-Nogo and Flanker tasks

Lesage

Sutherland

Ross

et al. 2019

Preprint

View full text Add to dashboard Cite

Cognitive deficits during nicotine withdrawal may contribute to smoking relapse. However, interacting effects of chronic nicotine dependence and acute nicotine withdrawal on cognitive control are poorly understood. Here, we examine the effects of nicotine dependence (trait; smokers versus non-smoking controls), and acute nicotinic stimulation (state; administration of nicotine and varenicline, two FDAapproved smoking cessation aids, during abstinence), on two well-established tests of cognitive control, the Go-Nogo task and the Flanker task, during fMRI scanning. We compared performance and neural responses between these four pharmacological manipulations in a double-blind, placebo-controlled crossover design. As expected, performance in both tasks was modulated by nicotine dependence, abstinence and pharmacological manipulation. However, effects were driven entirely by conditions that required less cognitive control. When demand for cognitive control was high, abstinent smokers showed no deficits. By contrast, acutely abstinent smokers showed performance deficits in easier conditions and missed more trials. Go-Nogo fMRI results showed decreased inhibition-related neural activity in right anterior insula and right putamen in smokers and decreased dorsal anterior cingulate cortex activity on nicotine across groups. No effects were found on inhibition-related activity during the Flanker task, or on error-related activity in either task. Given robust nicotinic effects on physiology and behavioral deficits in attention, we are confident that pharmacological manipulations were effective. Thus, findings fit a recent proposal that abstinent smokers show decreased ability to divert cognitive resources at low or intermediate cognitive demand, while performance at high cognitive demand remains relatively unaffected, suggesting a primary attentional deficit during acute abstinence.

show abstract

“…Nicotine use via tobacco products accounts for over 5 million deaths annually and billions of dollars in economic cost to society (World Health Organization, 2008). Though several pharmacotherapies have been FDA-approved for the management of nicotine use disorder (e.g., varenicline, bupropion, nicotine replacement therapy (NRT)), these medications are not effective for all smoking populations (Dhelaria et al, 2012; Hajek et al, 2009) and new medication approaches with novel mechanisms of action are urgently needed (Cahill et al, 2016; Yilmazel Ucar et al, 2014 for review).…”

Section: Introductionmentioning

confidence: 99%

Effects of lorcaserin (Belviq®) on nicotine- and food-maintained responding in non-human primates

Jacobs

Barkin

Kohut³

et al. 2017

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Background Accumulating evidence suggests that the FDA-approved serotonin 5HT2C receptor agonist, lorcaserin (Belviq®), may be a promising candidate for the management of substance use disorders, including nicotine addiction. The present study was conducted to determine the efficacy and selectivity of acute or continuous lorcaserin treatment for decreasing the reinforcing effects of nicotine in a primate species. Methods Adult rhesus monkeys (n=4) with a history of nicotine self-administration (>2 years) responded for injections of nicotine (0.32–100 µg/kg IV) or food pellets under a fixed-ratio schedule of reinforcement during daily 100-min sessions. When responding was stable, lorcaserin was administered either as an acute pretreatment (0.1–1.0 mg/kg, IM) or by continuous infusion (0.1 mg/kg/hr, SC for 3–5 days). Daily activity patterns were also monitored immediately following experimental sessions. Results Results indicate that acute lorcaserin pretreatment produced significant and dose-dependent decreases in nicotine-maintained responding across a >100-fold range of self-administered nicotine doses. Continuous lorcaserin treatment decreased intake of 10 µg/kg/inj nicotine to about 50% of baseline values. Food-maintained responding was only moderately decreased in 3 of 4 subjects after acute administration and unaffected in all subjects during continuous treatment. Daily activity also was significantly decreased—to ≤50% of control values—following experimental sessions in which acute lorcaserin was administered. Conclusions These data indicate that lorcaserin reduces IV self-administration of nicotine at a dose that decreases motoric activity but less consistently disrupts food-maintained responding. Further research into lorcaserin’s potential utility for the management of nicotine dependence is warranted.

show abstract

Nicotine receptor partial agonists for smoking cessation

Cited by 291 publications

References 213 publications

Smoking and the risk of type 2 diabetes

Smoking and the risk of type 2 diabetes

Nicotine dependence (trait) and acute nicotinic stimulation (state) modulate attention but not cognitive control: converging fMRI evidence from Go-Nogo and Flanker tasks

Effects of lorcaserin (Belviq®) on nicotine- and food-maintained responding in non-human primates

Contact Info

Product

Resources

About